2024-03-27 03:22:12
A study showed that terzepatide, approved for controlling blood sugar in patients with type 2 diabetes, has positive effects on both weight loss and blood sugar control in patients with type 1 diabetes.
The results of a study on the effects of terzepatide in overweight and obese adult patients with type 1 diabetes conducted by Dr. Satish Garg, Department of Endocrinology, University of Colorado School of Medicine, USA, were published in Libertpub on the 21st (doi.org/10.1089/dia. 2024.0050).
Terzepatide, a GLP-1·GIP dual agonist, first obtained FDA approval as a diabetes drug (brand name: Maunjaro) for patients with type 2 diabetes, and then changed the same ingredient to an obesity treatment (brand name: Zebbound) by the FDA at the end of last year. Approval has been obtained.
Terzepatide showed both weight loss and blood sugar improvement effects in overweight and obese patients with type 1 diabetes.
In Korea, it was approved as an adjunct to diet and exercise therapy to control blood sugar levels in patients with type 2 diabetes.
The researchers conducted a clinical trial on overweight and obese type 1 diabetic patients to determine the effect of terzepatide on type 1 diabetic patients who require insulin administration.
62 patients who were prescribed terzepatide (administered once a week) and 37 patients who were not prescribed terzepatide were followed up and changes in body mass index (BMI) and weight were compared at 3 months and 1 year.
The average (±SD) dose of terzepatide at 3 months was 5.6±1.9 mg, and the dose was increased to 9.7±3.3 mg at 1 year.
As a result of the analysis, BMI and weight loss were greater in the terzepatide-treated group than in the non-treated group at all time points (average weight loss of 18.5%).
HbA1c began to decline as early as 3 months in the treatment group and was maintained throughout the 1-year follow-up period (-0.67% for 1 year).
As blood sugar decreased, the insulin dosage also decreased throughout the 1-year follow-up period from the 3rd month.
Improvements in diabetes indicators such as TIR and TAR as well as blood sugar were observed, but no cases of severe hypoglycemia or hospitalization due to DKA were reported.
The researchers said, “Through this study, terzepatide showed an average of 18.5% weight loss and blood sugar improvement in overweight and obese populations with type 1 diabetes,” and added, “To ensure safe use in type 1 patients, we conducted a large-scale, prospective, randomized trial.” “There is a need to conduct clinical trials,” he added.
1711516748
#Terzepatide #effective #patients #type #diabetes